Fortress Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fortress Biotech, Inc. on February 22, 2026. The filing discloses two material definitive agreements entered into on the same date: the sale of a Priority Review Voucher (PRV) by its majority-owned subsidiary, Cyprium Therapeutics, Inc., and an amendment to its existing credit facility with Oaktree Fund Administration, LLC.
Key Financial Metrics and Agreements
- PRV Sale Proceeds: Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher for $205 million in cash upon closing.
- Debt Obligations: As of the report date, approximately $29.5 million is outstanding under the Loan Agreement with Oaktree.
- Expected Inflows to Fortress: Fortress Biotech expects to receive an aggregate of at least $100.0 million from Cyprium via future dividends and intercompany agreements following the PRV sale.
- Ownership Stake: Fortress Biotech owns approximately 80.4% of Cyprium's outstanding common stock on an as-converted basis.
Material Changes and Covenant Amendments
The Second Amendment to the Credit Agreement significantly alters financial covenants contingent on the PRV sale and loan balance levels:
- Covenant Relief: If the loan balance is $\le$ $15.0 million and the PRV proceeds are received, the Minimum Net Sales, Capital Raise, and Minimum JMC Stake covenants will no longer apply. The Minimum Liquidity requirement will be reduced to $2.0 million.
- Further Relief: If the loan balance is $\le$ $10.0 million, all aforementioned covenants (including Minimum Liquidity) will cease to apply.
- Mandatory Prepayment: Upon the PRV monetization event, the Company is obligated to make a mandatory prepayment of $10.0 million principal, plus accrued interest and the Yield Protection Premium.
- Repayment of Advances: Cyprium must repay amounts advanced by Fortress Biotech under a promissory note.
Outlook, Risks, and Contingencies
The transaction is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period. The actual amount Fortress Biotech receives from Cyprium is subject to several variables:
- Cyprium's obligation to pay 20% of PRV proceeds to the National Institutes of Health.
- Cyprium's tax obligations on the income.
- Redemption of Cyprium's 9.375% Perpetual Preferred Stock.
- Future dividends approved by Cyprium's Board of Directors.
Management includes standard forward-looking statements regarding the uncertainty of transaction completion, regulatory approvals, and the ability to secure additional funding.
Investor Verification Checklist
- Confirm the closing of the PRV Asset Purchase Agreement and the receipt of the $205 million by Cyprium.
- Verify the exact net proceeds distributed to Fortress Biotech after NIH payments, taxes, and preferred stock obligations.
- Monitor the mandatory $10.0 million prepayment on the Oaktree loan and the resulting reduction in outstanding debt.
- Review the subsequent periodic report for the full text of the PRV APA and the Second Amendment to the Credit Agreement.
- Assess the impact of the covenant relief on the company's financial flexibility and future capital raise requirements.